Skip to main content Skip to footer
Algernon Health Inc
  • Home
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Medical & Scientific Advisors
  • Alzheimer’s
    • Overview
    • AD Clinics
    • Markets
    • Resources
  • Pipeline
    • Overview
    • NP-251 (Repirinast)
    • AP-188 (DMT)
  • Companies
    • Algernon NeuroScience
  • News & Media
    • News Releases
    • IR Calendar
    • Presentations
    • Videos/Articles
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEDAR
    • Governance
  • Contact

We are currently in the process of updating our web site to reflect the announced plans to change our company name from Algernon Pharmaceuticals to Algernon Health. Please visit again soon as these changes continue to take effect across the entire web site.

News Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • News Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Annual General Meeting
    • Analysts
  • Stock Data
    • CSE:AGN
    • OTCQB:AGNPF
    • XFRA:AGW0
  • SEDAR
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • News Releases
  • IR Calendar
  • Email Alerts
Apr 04, 2019 7:00am EDT

Algernon Pharmaceuticals Appoints Leading Inflammatory Bowel Disease Expert Dr. Walter Reinisch to Its Medical and Scientific Advisory Board

Apr 01, 2019 7:00am EDT

Algernon Pharmaceuticals Announces Reduction of Key Secondary Marker of Fibrosis in Pre-Clinical NASH Study

Mar 21, 2019 7:00am EDT

Algernon Pharmaceuticals Appoints Leading Liver Disease Expert Dr. Arun Sanyal to Its Medical and Scientific Advisory Board

Mar 12, 2019 11:46pm EDT

Algernon Retains Renmark Financial Communications

Feb 25, 2019 7:00am EST

Algernon Pharmaceuticals Expands Its Research Program to Include Idiopathic Pulmonary Fibrosis

Feb 19, 2019 7:00am EST

Algernon Pharmaceuticals Begins Trading on The CSE Under The Symbol AGN

  • Previous Pagearrow_back
  • Page 1…
  • …
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • Page 20
  • Page 21
  • Page 22
  • Page 23
rss_feed News RSS
  • Visit us on Facebook

    Facebook

  • Visit us on Twitter

    Twitter

  • Visit us on LinkedIn

    LinkedIn

  • Email Alerts
  • Email Alerts
  • Contacts
  • RSS News Feed
©2025 Algernon Health Inc. All Rights Reserved.
Privacy Policy Sitemap